GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA
Delisted
GEVA was delisted on the 22nd of June, 2015.
120 hedge funds and large institutions have $2.42B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2014 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 43 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less call options, than puts
Call options by funds: $ | Put options by funds: $
31% less capital invested
Capital invested by funds: $3.53B → $2.42B (-$1.11B)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Holders
120
Holding in Top 10
2
Calls
$8.81M
Puts
$12.6M
Top Buyers
| 1 | +$38.9M | |
| 2 | +$27.9M | |
| 3 | +$18.7M | |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$15.3M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$13.4M |
Top Sellers
| 1 | -$27.4M | |
| 2 | -$18.1M | |
| 3 | -$12.7M | |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$11.9M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$5.42M |